Business Context and Reporting Period
This Form 8-K Current Report from Novavax, Inc. (NVAX) covers events occurring on March 10, 2025, with the report filed on March 11, 2025. The filing addresses significant changes to the Company's Board of Directors, including a resignation and a new appointment.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial performance data. Consequently, there are no reported figures for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
- Resignation: James F. Young, Ph.D., resigned from the Board of Directors effective March 10, 2025. The filing states this resignation is not the result of any disagreement with the Company regarding operations, policies, or practices.
- Leadership Appointments:
- Margaret G. McGlynn was appointed Chairperson of the Board.
- Richard H. Douglas, Ph.D. was appointed Chairperson of the Research and Development Committee.
- New Director Appointment: John W. Shiver, Ph.D., was appointed to the Board to fill the vacancy left by Dr. Young. He serves as a Class III director until the 2025 annual meeting and was appointed to the Research and Development Committee.
Compensation and Governance Details
Dr. Shiver's appointment includes specific compensatory arrangements under the Non-Employee Director Compensation Program:
- Initial Equity Grant: Granted on March 10, 2025, consisting of an option to purchase 35,770 shares and 23,480 restricted stock units (RSUs). The aggregate grant date fair value is approximately $525,000.
- Vesting Schedule: The initial grant vests in three equal annual installments over three years, contingent on continued service.
- Future Grants: Annual equity grants (approx. $350,000 fair value) will be made beginning at the 2026 second quarter meeting, vesting in full on the first anniversary.
- Independence: The Board determined Dr. Shiver qualifies as independent under Nasdaq listing standards.
Investor Verification Checklist
- Verify the independence status of the newly appointed director, John W. Shiver, and his specific qualifications for the Research and Development Committee.
- Review the Company's Definitive Proxy Statement on Schedule 14A (filed April 29, 2024) for details on the cash compensation component for non-employee directors.
- Confirm the impact of the Board composition changes on the Company's strategic direction, particularly regarding R&D oversight.
- Note that this filing contains no financial updates; refer to the most recent 10-K or 10-Q for financial health metrics.